Investigational drug · Phase 3
EIK1001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Melanoma, NSCLC, Non Small Cell Lung Cancer (Squamous or Non Squamous).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "EIK1001"
First trial start
2024
Feb 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EIK1001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Melanoma
- NSCLC
- Non Small Cell Lung Cancer (Squamous or Non Squamous)
- Stage 4 NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "EIK1001" as an intervention, largest first.
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.Pivotal-lookingRecruiting
Eikon TherapeuticsIndustry
NCT07365319 · 750 participants (planned) · Start Jun 15, 2026 · Primary completion Dec 31, 2035
Drug: EIK1001; Pembrolizumab (KEYTRUDA®) and 4 more · For: Non Small Cell Lung Cancer (Squamous or Non Squamous); Stage 4 NSCLC
Sites: Daphne, Alabama; Glendale, California; Orange, California · 52 sites in all
- Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.Pivotal-lookingRecruiting
Eikon TherapeuticsIndustry
NCT06697301 · 740 participants (planned) · Start May 22, 2025 · Primary completion Dec 2035
Drug: EIK1001; Pembrolizumab (KEYTRUDA® ) · For: Advanced Melanoma
Sites: Chandler, Arizona; Hot Springs, Arkansas; Los Angeles, California · 127 sites in all
- BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With PembrolizumabCompleted
Eikon TherapeuticsIndustry
NCT03486301 · 87 participants · Start Feb 15, 2018 · Primary completion Mar 31, 2024
Drug: BDB001 (EIK1001); Pembrolizumab · For: Tumor, Solid
Sites: Sarasota, Florida; Morristown, New Jersey; Nashville, Tennessee · 5 sites in all
- A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCActive, not recruiting
Eikon TherapeuticsIndustry
NCT06246110 · 70 participants (planned) · Start Feb 6, 2024 · Primary completion Dec 2026
Drug: EIK1001; Pembrolizumab and 3 more · For: NSCLC
Sites: Daphne, Alabama; Chandler, Arizona; Fresno, California · 38 sites in all
Eikon TherapeuticsIndustry
NCT04196530 · 40 participants · Start Nov 21, 2019 · Primary completion Jul 31, 2024
Drug: BDB001 (EIK1001); Atezolizumab · For: Tumor, Solid
Sites: Los Angeles, California; Sarasota, Florida; Nashville, Tennessee · 5 sites in all
Eikon TherapeuticsIndustry
NCT04840394 · 1 participants · Start Jun 22, 2021 · Primary completion Mar 31, 2024
Drug: BDB018; Pembrolizumab · For: Tumor, Solid
Sites: Sarasota, Florida; Grand Rapids, Michigan; San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Examination of the potential clinical application of 5DEX-0509R, the tumor macrophage-targeting nanomedicine.
Matsuda K, Ota Y, Uemachi H, et al. · Cytokine 2025
Also in development for Advanced Melanoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- BrenetafuspIMC-F106CPhase 32 trials
Immunocore Ltd · Select Advanced Solid Tumors, Advanced Melanoma
- RO7198457Autogene CevumeranPhase 24 trials
Roche (Genentech) · Colorectal Cancer Stage II, Colorectal Cancer Stage III, Adenocarcinoma, Pancreatic Ductal
- T3011Phase 24 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Advanced Solid Tumors, Nonmuscle-invasive Bladder Cancer, Solid Tumor
- LM103 TILsPhase 22 trials
Suzhou BlueHorse Therapeutics Co., Ltd. · Advanced Melanoma, Non-Small Cell Lung Cancer
- OPM-101Phase 21 trial
Oncodesign Precision Medicine · Advanced Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.